innoVitro
As a CRO, innoVitro specializes in human-cell analytics for drug safety, toxicity, and efficacy in preclinical cardiac risk assessment.
Anivance AI Corporation
Anivance AI combines organ chips with Multi-Agent AI. With 35 patents and global collaborations, we deliver plug-and-play platforms and LaaS services, supporting rare disease and inhalation models, diverse preclinical studies, and predictive, clinically-relevant data for accelerated drug discovery.
Optics11
Optics11Life develops cutting-edge life science tools using optical fiber sensing technology. The two main products are: The Nanoindentation Platform (Pavone, Piuma and Chiaro) and The Cuore 3D Engineered Muscle Contractility Platform
Nilogen Oncosystems
Provision of untouched intact tumor tissue platform to allow for the investigation of clinical relevant biomarkers, mechanism of action, safety and efficacy of therapeutics.
BiomimX
BiomimX develops the next generation of beating organs-on-chips. uBeat® Platforms and connected hardware provide 3D miniaturized constructs with a tunable mechanical stimulation to model human organs’ function and diseases. uBeat® products and customized drug screening services are available.
Newcells Biotech
Newcells Biotech uses 3D in vitro modelling expertise to develop nephrotoxicity and renal transporter assays that most accurately predict in vivo outcomes, as well as producing fully developed hiPSC-derived Retinal Organoids.
AlveoliX
AlveoliX has developed an adaptable organ-on-chip platform that enables the modelling of all tissue barriers, including the associated mechanical forces. Our technology is suitable for a wide range of applications including drug safety and efficacy testing, inhalation toxicology assessment and answering fundamental research questions. Our technology can be implemented in your laboratory, or utilised through our CRO services
InSphero
InSphero is the pioneer of industrial-grade, 3D-microtissue-based assay solutions and scaffold-free 3D organ-on-a-chip technology. The company specializes in liver toxicology, metabolic diseases (e.g., T1 & T2 diabetes and NAFLD & NASH liver disease), and immuno oncology.
Lena Biosciences
Lena Biosciences offers Perfused Organ Panel MPS with a Blood Substitute hemoglobin analog that yields a log-fold increase in CYP450 activity in primary human hepatocytes to identify mitotoxic metabolites and DILI. Services focus on efficacy and toxicity in liver, brain, tumor, and blood models.